RedHill Biopharma (RDHL) Cash from Investing Activities: 2012-2022
Historic Cash from Investing Activities for RedHill Biopharma (RDHL) over the last 11 years, with Sep 2022 value amounting to -$22,000.
- RedHill Biopharma's Cash from Investing Activities rose 99.74% to -$22,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $11.8 million, marking a year-over-year increase of 411.65%. This contributed to the annual value of -$9,000 for FY2024, which is 325.00% down from last year.
- Per RedHill Biopharma's latest filing, its Cash from Investing Activities stood at -$22,000 for Q3 2022, which was up 86.50% from -$163,000 recorded in Q2 2022.
- RedHill Biopharma's Cash from Investing Activities' 5-year high stood at $11.7 million during Q3 2019, with a 5-year trough of -$49.8 million in Q2 2020.
- Moreover, its 3-year median value for Cash from Investing Activities was $387,000 (2021), whereas its average is -$3.3 million.
- Per our database at Business Quant, RedHill Biopharma's Cash from Investing Activities plummeted by 2,897.71% in 2019 and then skyrocketed by 2,093.02% in 2022.
- RedHill Biopharma's Cash from Investing Activities (Quarterly) stood at $175,000 in 2018, then tumbled by 2,897.71% to -$4.9 million in 2019, then skyrocketed by 260.36% to $7.9 million in 2020, then slumped by 55.46% to $3.5 million in 2021, then skyrocketed by 99.74% to -$22,000 in 2022.
- Its last three reported values are -$22,000 in Q3 2022, -$163,000 for Q2 2022, and $8.5 million during Q1 2022.